GoodRx Holdings, Inc. - Q2 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2024. GoodRx operates a digital healthcare platform enabling consumers to compare prescription drug prices and access negotiated discounts via codes. The company primarily generates revenue from pharmacy benefit managers (PBMs) and offers subscription services, pharma manufacturer solutions, and telehealth.
Key Financial Metrics
| Metric | Q2 2024 | Q2 2023 | YTD 2024 | YTD 2023 |
|---|---|---|---|---|
| Revenue | $200.6 million | $189.7 million | $398.5 million | $373.7 million |
| Net Income | $6.7 million | $58.8 million | $5.7 million | $55.5 million |
| Operating Income | $19.9 million | $18.3 million | $27.3 million | $29.6 million |
| Adjusted EBITDA | $65.4 million | $53.5 million | $128.2 million | $106.7 million |
| Cash and Equivalents | $524.9 million | $672.3 million (Dec 2023) | N/A | |
| Debt (Net) | $652.7 million | $656.5 million (Dec 2023) | N/A | |
| Operating Cash Flow (YTD) | N/A | $52.3 million | $62.2 million |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 6% year-over-year (YoY) in Q2 and 7% YoY for the six months ended June 30, 2024. Prescription transactions revenue grew 7% driven by an 8% increase in Monthly Active Consumers.
- Profitability Decline: Net income dropped significantly to $6.7 million in Q2 2024 from $58.8 million in Q2 2023. This decline is primarily attributed to a one-time discrete tax benefit of $46.7 million recognized in Q2 2023 due to the release of a valuation allowance, which did not recur in 2024.
- Expense Trends: Sales and marketing expenses increased 21% YoY in Q2, driven by higher payroll costs and advertising spend. Conversely, cost of revenue decreased 27% YoY due to lower headcount following restructuring.
- Subscription Decline: Subscription revenue decreased 8% YoY as the "Kroger Savings" offering was sunset in July 2024, reducing total subscription plans from 969,000 to 696,000.
Guidance, Outlook, and Risks
- Debt Restructuring: On July 10, 2024 (subsequent to period end), GoodRx amended its credit agreement to establish a new $500 million term loan maturing in 2029, repaying the previous term loan in full. This extends the maturity of the majority of its revolving credit facility to 2029.
- Legal Contingencies: The company accrued a $27.5 million liability for a proposed class action settlement regarding consumer privacy. Negotiations remain ongoing, and the final loss may differ from the estimate. Additionally, a securities class action lawsuit was filed in April 2024 regarding the "grocer issue," for which no loss has been accrued as it is not yet probable.
- Market Risks: Management notes that recent store closures by Rite Aid and other retailers may have a transient adverse impact on prescription volume. Heightened renegotiations between pharmacies and PBMs could also affect revenue.
- Capital Allocation: The company authorized a new $450 million stock repurchase program in February 2024. As of June 30, 2024, $295.5 million remained available. Significant repurchases ($151.4 million) occurred in Q1 2024 from related parties.
Investor Verification Checklist
- Tax Impact: Verify the sustainability of net income margins by excluding the one-time $46.7 million tax benefit from Q2 2023 when comparing profitability.
- Legal Exposure: Monitor the status of the $27.5 million accrued privacy settlement and the potential liability from the securities class action lawsuit filed in April 2024.
- Debt Terms: Review the terms of the new $500 million term loan finalized in July 2024, specifically interest rates and covenants, to assess future interest expense.
- Subscription Churn: Assess the long-term impact of the Kroger Savings sunset on total subscription revenue and whether the higher-margin "Gold" subscription can fully offset the volume loss.
- Pharmacy Landscape: Evaluate the actual impact of Rite Aid and other retailer store closures on prescription transaction volume in the second half of 2024.